#Sovaldi

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Among those without cirrhosis, treating for an additional four weeks is unnecessary.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Ending the epidemic is going to require addressing the fact that certain individuals are at high risk of reinfection after a cure.

Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.

In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

The drugmaker is accused of infringing on a patent held by rival Merck & Co. over its formulas for Sovaldi and Harvoni treatment.

These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.

In early research in cell cultures and mice, scientists found Sovaldi could possibly thwart Zika’s harmful effects on unborn babies.

Fighting Hep C, using the fury to stoke the fire within.

The U.S. FDA released November 13, 2017 new updates on Hepatitis C treatment medications.

People who beat hepatitis C virus (HCV) see their health-related quality of life (HRQL) improve—and not just in the short term.